INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2004/015594

A. CLASSIFICATION OF SUBJECT MATTER
Int.Cl[7] C12N5/10, C07K14/745, C12N15/12, C07K14/46, C12P21/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
Int.Cl[7] C12N5/10, C07K14/745, C12N15/12, C07K14/46, C12P21/02

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
JSTPlus(JOIS), BIOSIS/WPI(DIALOG)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	JP 2003-510087 A (Genentech, Inc.), 18 March, 2003 (18.03.03), Full text & WO 01/23592 A2 & EP 1220934 A2 & US 6586206 B1	1-22 23
X A	Lin G. et al., Stable cell lines expressing baculovirus P35: resistance to apoptosis and nutrient stress, and increased glycoprotein secretion, In Vitro Cell Dev.Biol.Anim., 2001, Vol.37, No.5, pages 293 to 302	1-22 23
X A	Greenberg C.S. et al., Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting, J.Clin. Invest., 1985, Vol.75, No.5, pages 1463-1470	23 1-22

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
02 February, 2005 (02.02.05)	22 February, 2005 (22.02.05)
Name and mailing address of the ISA/ Japanese Patent Office Facsimile No.	Authorized officer Telephone No.

Form PCT/ISA/210 (second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2004/015594

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	Roy S.N. et al., Assembly and secretion of recombinant human fibrinogen, J.Biol.Chem., 1991, Vol.266, No.8, pages 4758 to 4763	23 1-22
X A	Morita T. et al., Purification and properties of prothrombin activator from the venom of Echis carinatus, J.Biochem., 1978, Vol.83, No.2, pages 559 to 570	23 1-22

The substance as set forth in claim 23 is specified as "a protein high-produced by using a recombinant animal cell as set forth in any of claims 1 to 17" and, therefore, involves any proteins produced by using these animal cells.

However, fibrinogen, ecarin and factor VIII are exclusively disclosed in the description as proteins produced by using these animal cells. Although the common technical knowledge at the point of the application is taken into consideration, the scope of substances obtained by the screening method cannot be specified. Thus, claim 23 is described in an unclear manner.

Such being the case, the search was made on fibrinogen, ecarin and factor VIII which are specifically presented in the description.